Ramipril Related Burning Mouth Syndrome: A Case Report

Öz

Burning mouth syndrome (BMS) or glossodynia is a disease characterized by oral burning or similar pain without clinically evident causative lesions or any other possible causes. Many factors are accepted as possible causes for this disease. Some drugs have also been reported to cause this syndrome. In this article case of burning mouth syndrome, which started after the use of angiotensin-converting enzyme (ACE) inhibitor ramipril and whose symptoms disappeared after discontinuation of the drug was presented.

Anahtar Kelimeler

• Angiotensin-converting enzyme inhibitor
• burning mouth syndrome
• ramipril

Ramipril İlişkili Yanan Ağız Sendromu: Vaka Sunumu

Öz

Yanan ağız sendromu (YAS) veya glossodini, klinik olarak belirli bir lezyon veya başka bir neden olmaksızın ağızda yanma veya benzeri ağrı ile karakterize olan bir hastalıktır. Birçok faktör bu hastalığın olası nedenleri olarak kabul edilmektedir. Bazı ilaçların da bu sendroma neden olduğu bildirilmiştir. Bu yazıda anjiyotensin dönüştürücü enzim (ACE) inhibitörü ramipril kullanımı sonrası başlayan ve ilaç kesildikten sonra semptomları kaybolan yanan ağız sendromu olgusu sunulmuştur.

Anahtar Kelimeler

• Anjiyotensin dönüştürücü enzim inhibitörü
• yanan ağız sendromu
• ramipril

Kaynakça

1. Bergdahl M, Bergdahl J. Burning Mouth Syndrome: Prevalence and associated factors. J Oral Pathol Med. 1999;28(8):350-354.
2. Zakrzewska J, Buchanan JA. Burning Mouth Syndrome. BMJ Clin Evid. 2016;01:1301.
3. Vellappally S. Burning Mouth Syndrome: A Review of the etiopathologic factors and management. J Contemp Dent Pract. 2016;117(2):171-6
4. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.
5. Grushka M, Epstein JB, Gorsky M. Burning mouth syndrome. Am Fam Physician. 2002;65(4):615-20.
6. Obara T, Naito H, Nojima T, Koga H, Nakao A. Burning mouth syndrome induced by Angiotensin-Converting Enzyme inhibitors. Cureus. 2020;12(11):e11376.
7. Lauria G, Majorana A, Borgna M, Lombardi R, Penza P, Padovani A, et al. Trigeminal small-fiber sensory neuropathy causes burning mouth syndrome. Pain. 2005;115(3):332-337.
8. Jääskeläinen SK, Woda A. Burning mouth syndrome. Cephalalgia. 2017;37(7):627-647.

9. Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, et al. Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells. Circ Res. 1997;81(5):848-56.
10. Katanosaka K, Banik RK, Giron R, Higashi T, Tominaga M, Mizumura K. Contribution of TRPV1 to the bradykinin-evoked nociceptive behavior and excitation of cutaneous sensory neurons. Neurosci Res. 2008;62(3):168-75.
11. Castells X, Rodoreda I, Pedrós C, Cereza G, Laporte J. Drug Points: Dysgeusia and burning mouth syndrome by eprosartan. BMJ. 2002;325:1277.
12. Boras VV, Brailo V, Juras DV. Ramipril induced burning mouth symptoms. Annual Research & Review in Biology. 2014;4(24),3945-3948.